Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2021-08-12 00:00:00 ET · period of report 2021-08-10 · accession 0001209191-21-051214 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-12 | 2021-08-10 | QNCX | Detke Michael J. | Chief Medical Off | S - Sale+OE | $100.00 | -10.0K | 0 | -100% | -$1.00M |
| D | 2021-08-12 | 2021-08-10 | QNCX | Detke Michael J. | Chief Medical Off | M - OptEx | $2.23 | +10.0K | 10.0K | New | +$22.3K |
| D | 2021-08-12 | 2021-08-10 | QNCX | Detke Michael J. | Chief Medical Off | M - OptEx | $0.00 | -10.0K | 92.4K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-10 | S | D | 10,000 | $100.00 | 0 | D | — | — | |
| 2 | Common | Common Stock | 2021-08-10 | M | A | 10,000 | $2.23 | 10,000 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2021-08-10 | M | D | 10,000 | $0.00 | 92,352 | D | $2.23 · — to 2028-11-27 | 10,000 Common Stock | (F2) The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022. |